First of its kind dual inflammasome inhibitor of both NLRP 1 and NLRP 3 with IND-enabling studies in 2023 CONCORD, Mass., July 6, 2023 /PRNewswire/ — Adiso Therapeutics, Inc., a clinical-stage biotechnology company developing novel medicines targeting chronic inflammatory diseases, today…